Our study found that SRD5A3 was highly expressed in most tumors, such as B-NHL, breast, liver, colorectal, and ovarian cancer, compared to normal control tissues, and that patients with SRD5A3 high expression had a poor OS. Here, SRD5A3 is linked to ovarian carcinoma.